Verified employee & interview reviews

AstraZeneca India Reviews

Bengaluru, Karnataka

5.0/ 5

3 reviews

AstraZeneca Pharma India Limited (AZPIL), established in 1979 and headquartered in Bengaluru, Karnataka, operates as a prominent science-led biopharmaceutical company. It is a listed subsidiary of AstraZeneca Pharmaceuticals AB, Sweden, which itself is an indirect subsidiary of the global parent entity, AstraZeneca PLC, UK. The company serves as the primary operational wing for the AstraZeneca portfolio within India, covering extensive activities across manufacturing, sales, marketing, and distribution of pharmaceutical products, alongside coordinating clinical trial services for its overseas group. The core operations of AstraZeneca India span several major therapeutic business segments, primarily focusing on Oncology, Cardiovascular, Renal and Metabolism (CVRM), and Chronic Respiratory Diseases. In the CVRM segment, the company provides innovative medicines for critical conditions, including heart failure and chronic kidney disease, utilizing notable treatments like Forxiga (Dapagliflozin). Its oral antidiabetic drug portfolio features key drug classes such as SGLT2 inhibitors and DPP4 inhibitors, the latter comprising well-known brands like Onglyza (Saxagliptin) and Kombiglyze (Saxagliptin/Metformin). Within its oncology business, the company delivers targeted cancer therapies under prominent brand names like Tagrisso, Lynparza, Enhertu, and Imfinzi, with strategic expansions into indications like Biliary Tract Carcinoma and early breast cancer. The respiratory vertical features established treatments such as Symbicort and Fasenra, while its specialized Rare Disease unit commercializes therapies like Koselugo. Operating from its corporate office at Manyata Embassy Business Park in Bengaluru, AstraZeneca India employs a workforce dedicated to delivering life-changing medicines to patients. Financially, AstraZeneca Pharma India Limited is publicly traded on both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE) under the ticker ASTRAZEN. The company reported a consolidated annual revenue from operations of INR 2,276 crore and maintains a robust market position within the multinational pharmaceutical industry sector in India. Leadership is driven by Managing Director and Director Praveen Rao Akkinepally alongside Whole-Time Director and CFO Bhavana Agrawal. AstraZeneca India integrates global corporate governance and sustainability frameworks into its local operations, focusing on three core priority pillars: improving access to healthcare, environmental protection, and driving ethics and transparency. Through a combination of research-backed bio-pharmaceutical developments, strategic collaborations with international healthcare entities, and localized management applications like the K+ Connect platform for hyperkalemia management, the company remains dedicated to advancing healthcare delivery systems, early disease intervention, and expanding patient care networks across the Indian subcontinent.